Abstract 2060P
Background
The aim of the study is to identify the prevalence and predictors of mental adjustment to cancer in patients who were going to resect lung for non-small cell lung cancer in Korea.
Methods
A total of 697 patients were recruited from September 2021 to October 2022 and completed a survey questionnaire of the Korean version of Mini-Mental Adjustment to Cancer (K-Mini-MAC) which higher mean score denote worse mental adjustment, except for positive attitude (PA) domain. Multivariable logistic regression was analyzed to determine potential predictors of poor adjustment to cancer for each domain of K-mini-MAC, which was defined by the mean score of 2.5 or higher, while PA domain was defined by mean score of 2.5 or lower.
Results
The mean age of study population was 63.2 ± 0.4 years old and 50.4% was male. The proportion of poor mental adjustment was 6.0% (Helpless/Hopeless [HH] domain), 29.6% (Anxious Preoccupation [AP] domain), 19.1% (PA domain), and 30.1% (Cognitive Avoidance [CA] domain). The mean score of each domain was 1.60 ± 0.02 (HH), 2.17 ± 0.02 (AP), 2.83 ± 0.02 (PA), and 2.62 ± 0.02 (CA). Younger age (<65 years old, aOR 1.78, 95% CI 1.15-2.76) and having comorbidity (aOR 1.64, 95% CI 1.09-2.45) were associated with poor mental adjustment in AP domain, while current alcohol drinking was associated with better mental adjustment in AP domain (aOR 0.56, 95% CI 0.32-0.96, vs. non-alcohol drinker). Poor mental adjustment in PA domain was predicted based on Lower education level (≤ middle school, aOR 1.97, 95% CI 1.12-3.46; high school, aOR 2.31, 95% CI 1.23-4.36, vs. ≥ university). There was no significant predictor for mental adjustment in HH and CA domain.
Conclusions
Younger, non-alcohol drinker, having comorbidity and lower educational level was associated with a poor adjustment to cancer. Interventions to help with adjustment to cancer should be focused particularly on these group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Korean government (Grant Number: MSIT; 2019R1A2C2009751).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06